1
|
Zhang L, Zhai BZ, Wu YJ, Wang Y. Recent progress in the development of nanomaterials targeting multiple cancer metabolic pathways: a review of mechanistic approaches for cancer treatment. Drug Deliv 2023; 30:1-18. [PMID: 36597205 PMCID: PMC9943254 DOI: 10.1080/10717544.2022.2144541] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Cancer is a very heterogeneous disease, and uncontrolled cell division is the main characteristic of cancer. Cancerous cells need a high nutrition intake to enable aberrant growth and survival. To do so, cancer cells modify metabolic pathways to produce energy and anabolic precursors and preserve redox balance. Due to the importance of metabolic pathways in tumor growth and malignant transformation, metabolic pathways have also been given promising perspectives for cancer treatment, providing more effective treatment strategies, and target-specific with minimum side effects. Metabolism-based therapeutic nanomaterials for targeted cancer treatment are a promising option. Numerous types of nanoparticles (NPs) are employed in the research and analysis of various cancer therapies. The current review focuses on cutting-edge strategies and current cancer therapy methods based on nanomaterials that target various cancer metabolisms. Additionally, it highlighted the primacy of NPs-based cancer therapies over traditional ones, the challenges, and the future potential.
Collapse
Affiliation(s)
- Ling Zhang
- Reproductive Medicine Center, Department of Reproductive Endocrinology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China,CONTACT Ling Zhang Reproductive Medicine Center, Department of Reproductive Endocrinology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou310014, Zhejiang, China
| | - Bing-Zhong Zhai
- Hangzhou Municipal Center for Disease Control and Prevention, Hangzhou, Zhejiang, 310021, China
| | - Yue-Jin Wu
- Institute of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, 310013, China
| | - Yin Wang
- Institute of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, 310013, China,; Yin Wang Institute of Food Science and Engineering, Hangzhou Medical College, 182 Tianmushan Road, Hangzhou310013, Zhejiang, China
| |
Collapse
|
2
|
Qu XF, Zhai BZ, Hu WL, Lou MH, Chen YH, Liu YF, Chen JG, Mei S, You ZQ, Liu Z, Zhang LJ, Zhang YH, Wang Y. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells. Eur J Nutr 2022; 61:1823-1836. [PMID: 34997266 PMCID: PMC9106599 DOI: 10.1007/s00394-021-02768-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 11/30/2021] [Indexed: 12/28/2022]
Abstract
Purpose Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus and is characterized by myocardial hypertrophy and myocardial fibrosis. Pyrroloquinoline quinone (PQQ), a natural nutrient, exerts strong protection against various myocardial diseases. Pyroptosis, a type of inflammation-related programmed cell death, is vital to the development of DCM. However, the protective effects of PQQ against DCM and the associated mechanisms are not clear. This study aimed to investigate whether PQQ protected against DCM and to determine the underlying molecular mechanism. Methods Diabetes was induced in mice by intraperitoneal injection of streptozotocin, after which the mice were administered PQQ orally (10, 20, or 40 mg/kg body weight/day) for 12 weeks. AC16 human myocardial cells were divided into the following groups and treated accordingly: control (5.5 mmol/L glucose), high glucose (35 mmol/L glucose), and HG + PQQ groups (1 and 10 nmol/L PQQ). Cells were treated for 24 h. Results PQQ reduced myocardial hypertrophy and the area of myocardial fibrosis, which was accompanied by an increase in antioxidant function and a decrease in inflammatory cytokine levels. Moreover, myocardial hypertrophy—(ANP and BNP), myocardial fibrosis—(collagen I and TGF-β1), and pyroptosis-related protein levels decreased in the PQQ treatment groups. Furthermore, PQQ abolished mitochondrial dysfunction and the activation of NF-κB/IκB, and decreased NLRP3 inflammation-mediated pyroptosis in AC16 cells under high-glucose conditions. Conclusion PQQ improved DCM in diabetic mice by inhibiting NF-κB/NLRP3 inflammasome-mediated cell pyroptosis. Long-term dietary supplementation with PQQ may be greatly beneficial for the treatment of DCM. Graphical abstract Diagram of the underlying mechanism of the effects of PQQ on DCM. PQQ inhibits ROS generation and NF-κB activation, which stimulates activation of the NLRP3 inflammasome and regulates the expression of caspase-1, IL-1β, and IL-18. The up-regulated inflammatory cytokines trigger myocardial hypertrophy and cardiac fibrosis and promote the pathological process of DCM. ![]()
Collapse
Affiliation(s)
- Xue-Feng Qu
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Bing-Zhong Zhai
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Wen-Li Hu
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Min-Han Lou
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Yi-Hao Chen
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Yi-Feng Liu
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Jian-Guo Chen
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Song Mei
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Zhen-Qiang You
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Zhen Liu
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Li-Jing Zhang
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China
| | - Yong-Hui Zhang
- Department of Basic Medical Science, Chongqing Three Gorges Medical College, Tianxing Road 366th, Chongqing, 404120, People's Republic of China.
| | - Yin Wang
- Institute of Food Science and Engineering, Hangzhou Medical College, Tianmushan Road 182th, Hangzhou, 310013, Zhejiang, People's Republic of China.
| |
Collapse
|